The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero
Pharmacyclics, Inc. (PCYC)

Pharmacyclics is a biopharmaceutical company that designs, develops and commercializes therapies with a focus on product candidates that are small-molecule drugs for the treatment of cancer and immune-mediated diseases. Co.'s IMBRUVICA™ product has been developed for mantle cell lymphoma and chronic lymphocytic leukemia patients, who in each case have received at least one prior therapy. Co. also has three other product candidates in clinical development, including a Bruton's tyrosine kinase inhibitor targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa (PCI-27483), and a histone deacetylase inhibitor targeting in solid tumors and hematological malignancies.

Company Name:  Pharmacyclics, Inc.
Website:  www.pharmacyclics.com
Sector:  Biotechnology
Number of ETFs Holding PCYC:  36
Total Market Value Held by ETFs:  $642.13M
Total Market Capitalization:  $9.85B
% of Market Cap. Held by ETFs:  6.52%
October 31, 2014    4:55 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes



Buy (3.33 out of 4)
63rd percentile
(ranked higher than approx. 63% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Pharmacyclics, Inc. (PCYC) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.